Javanese Turmeric for Digestion and Dyspepsia: The European Regulatory Record, Read in Full

The main Curcuma zanthorrhiza page covers the digestive/choleretic claim well as pharmacology and tradition, but it discusses regulation only in Indonesia — the jamu / OHT / fitofarmaka tiers. What it does not mention at all is that temulawak also has a genuine, formal regulatory history in Europe, running back to the 1960s in the Netherlands and the 1970s in Germany, culminating in a 2014 European Union herbal monograph. This is a real gap worth closing, because the European record is unusually well documented — the EU assessment report is a public document that names the specific studies behind the indication, states their doses, and explains exactly why the indication is worded the way it is. Few herbs on this site have a primary source this precise. This page reads it in full, alongside the human pharmacology data it rests on.

Table of Contents

1. The Claim
2. A History Most Readers Do Not Expect: Europe Since 1963
3. The German Commission E Monograph
4. The 2014 EU Traditional-Use Monograph, in Full
5. What “Traditional Use” Actually Certifies — and What It Does Not
6. The Human Evidence Behind the Indication: Two Real Trials
7. The Regulator’s Own Arithmetic: Why the Indication Was Narrowed
8. The Underlying Mechanism, In the Regulator's Own Words
9. Appetite in Children: The Household Use
10. A Related but Distinct Finding: Gastroprotection From the Leaf, Not the Rhizome
11. Verdict and Evidence Tier
12. What Is Not Known
13. Practical Cautions
14. Key Research Papers
15. Connections

The Claim

Digestion is temulawak’s most defensible traditional use and, as the main page states, its least glamorous: a bitter root taken to ease fullness, sluggish digestion and flatulence, and traditionally linked to “insufficient bile secretion.” What makes this claim different from almost everything else on this site’s herb pages is that it has been formally examined, in public, by a government medicines regulator — twice, a generation apart — and both examinations reached essentially the same conclusion, for essentially the same stated reasons.

A History Most Readers Do Not Expect: Europe Since 1963

Curcuma xanthorrhiza rhizome has been a marketed medicinal product in Europe for over sixty years — not as an exotic import discovered recently, but as an ordinary pharmacy item. The European Medicines Agency’s own assessment report documents:

• The Netherlands, since at least 1963 — as a combination product (with Curcuma aromatica and Rhamnus purshiana, cascara bark) and, from 1979, as a standalone infusion.
• Germany, since at least 1976 — three separate licensed preparations: two ethanolic dry extracts in hard capsules and one acetone dry extract in a soft capsule, all still describable in the assessment report’s own present-tense market survey.

By the time the EU conducted its Europe-wide harmonisation review in 2012–2014, Germany was one of only two member states (alongside the Netherlands, where it appears combined with other ingredients) reporting an actual national marketing authorisation for the plant — the rest of the EU’s member states showed no registered product at all, meaning this is a real but geographically concentrated European tradition, centred on Germany and the Netherlands specifically, not a continent-wide one.

Back to Table of Contents

The German Commission E Monograph

Germany’s Commission E — the expert panel that reviewed herbal medicines for the German federal health authority from the 1970s to the 1990s, and whose monographs remain a standard reference in Western herbal medicine — issued a positive monograph for Curcumae xanthorrhizae rhizoma (Javanese turmeric) in 1990. Its approved indication, quoted in the standard Blumenthal compilation of Commission E monographs: “dyspeptic complaints, particularly based on functional affections of the biliary tract,” attributed to a “choleretic action.” The standard German posology was 2 g of dried root (or an equivalent preparation) daily, and the recorded side effects were mild: dry mouth, flatulence and gastric irritation with prolonged use.

The European Scientific Cooperative on Phytotherapy (ESCOP), a separate and later European expert body, reached a parallel conclusion in its own monograph (2009 supplement): “symptomatic treatment of mild digestive disturbances and minor biliary dysfunction.” Two independent European phytotherapy authorities, working a generation apart, landed on effectively the same indication using effectively the same reasoning — which is a meaningfully different situation from a single marketing claim repeated across product labels.

The 2014 EU Traditional-Use Monograph, in Full

The Commission E and ESCOP monographs are expert opinions, useful but not binding law. The document that actually governs what a European manufacturer may claim is the European Medicines Agency’s Community herbal monograph on Curcuma xanthorrhiza Roxb. rhizoma (reference EMA/HMPC/604600/2012), adopted by the Committee on Herbal Medicinal Products (HMPC) on 28 January 2014, after a formal public consultation. This is a primary regulatory document, not a summary or a press release, and it is worth quoting precisely because most herb pages on this site cannot point to anything this exact.

The approved indication, verbatim: “Traditional herbal medicinal product used for symptomatic treatment of digestive disturbances, such as feelings of fullness, slow digestion and flatulence.”

The approved posology, three forms:

• Herbal tea — 1 g of comminuted (cut/sliced) herbal substance in 100 mL boiling water as an infusion, 3 times daily.
• Dry extract, DER 20–50:1, ethanol 96% extraction — single dose 8–13 mg, 3 times daily.
• Dry extract, DER 9–12:1, acetone extraction — single dose 50–100 mg, 2 times daily.

Restrictions, verbatim from the monograph: not recommended for children and adolescents under 18 (“due to lack of adequate data”); if symptoms persist beyond 2 weeks or worsen, see a doctor; not recommended in pregnancy or lactation (safety not established); and — the warning discussed in full on the liver deep-dive — not recommended “in case of obstruction of the bile duct, cholangitis, liver disease, gallstones and any other biliary diseases,” because of the same bile-stimulating action the indication itself rests on.

Reported adverse effects, verbatim: “mild gastrointestinal symptoms such as dry mouth, flatulence and gastric irritation may occur. The frequency is not known.” No serious adverse events, and no reported case of overdose, appear anywhere in the assessment file.

Back to Table of Contents

What “Traditional Use” Actually Certifies — and What It Does Not

This is the point worth being precise about, because “approved by the European Medicines Agency” sounds, to an unfamiliar reader, like a stronger claim than it is. The EU herbal-monograph system (under Directive 2004/24/EC) has two tiers, and the monograph document itself is laid out as a two-column table — “Well-established use” beside “Traditional use” — for exactly this reason:

• Well-established use requires published scientific literature demonstrating that the product actually works — the closest EU equivalent to an efficacy standard, requiring real clinical trial evidence.
• Traditional use requires only documented use for at least 30 years (at least 15 within the EU) plus plausible pharmacology — explicitly not proof of efficacy.

In the actual Curcuma xanthorrhiza monograph, every single cell in the “Well-established use” column is blank, across all nine numbered sections of the document — composition, indication, posology, contraindications, warnings, pregnancy, adverse effects, pharmacodynamics, everything. Only the “Traditional use” column is populated. The assessment report’s own overall conclusion states this without hedging: “The available data are not sufficient to support a ‘Well Established Use’ indication for Javanese Turmeric.”

So what did HMPC actually certify? Not that temulawak treats dyspepsia. It certified that people have safely used a rhizome tea or extract for digestive discomfort for at least three decades, that the choleretic mechanism is pharmacologically plausible, and that the safety profile is mild enough not to need a doctor’s supervision for short-term, symptomatic, adult use. That is a real and useful certification — it is the reason a reader can be reasonably confident temulawak tea will not hurt them — and it is a categorically different thing from a clinical proof of effect. This is the general pattern behind every traditional-use registration on this site (horehound, yarrow, meadowsweet among them): tradition plus plausibility, not trial results.

The Human Evidence Behind the Indication: Two Real Trials

Unusually for a traditional-use monograph, this one rests on real, retrievable, PubMed-indexed human data — a research group at the University of North Sumatera in Medan, Indonesia, led by A. Rasyid, published two dose-ranging human studies on curcumin and the human gallbladder, both cited directly in the EU assessment report.

Study one (Rasyid & Lelo, 1999, Alimentary Pharmacology & Therapeutics): a randomised, double-blind, crossover study in 12 healthy volunteers (seven men, five women), comparing 20 mg oral curcumin against placebo. Gallbladder volume was measured serially by ultrasound. The two arms started statistically identical (15.74 vs 15.98 mL fasting volume). After curcumin, gallbladder volume fell progressively: 11.8% at 30 minutes, 16.8% at 60 minutes, 22.0% at 90 minutes, and 29.3% at 2 hours — each timepoint statistically significant against placebo. The paper’s own conclusion: “curcumin induces contraction of the human gall-bladder.”

Study two (Rasyid et al., 2002, Asia Pacific Journal of Clinical Nutrition): a follow-up dose-ranging study, again 12 healthy volunteers, randomised single-blind three-phase crossover, comparing 20, 40 and 80 mg curcumin doses directly against each other. Gallbladder volume reduction at 2 hours was dose-dependent: 34.1% at 20 mg, 51.2% at 40 mg, 72.3% at 80 mg (ANOVA, p<0.01). The paper’s stated aim was to find the dose producing 50% contraction — answer: roughly 40 mg — and it explicitly tested whether doubling the dose doubles the effect. It does not: the relationship is not linear, meaning the biggest jump in effect happens at the lower end of the dose range and further increases in dose deliver progressively smaller gains.

Read these two studies for exactly what they are. Both are real, published, peer-reviewed, and directly on point for the choleretic mechanism — this is meaningfully more than most traditional-use indications on this site can claim. But both tested isolated curcumin, described by the authors themselves as “an active compound of Curcuma xanthorrhiza and C. domestica” — that is, a constituent shared with ordinary turmeric, not confirmed as sourced from Javanese turmeric material specifically. Neither study measured a clinical outcome (dyspepsia symptom relief, bloating, satisfaction) — both measured a physiological surrogate, gallbladder volume on ultrasound. And both enrolled only 12 healthy volunteers, with no participant reporting a digestive complaint at baseline. This is real, human, dose-responsive pharmacology for a shared Curcuma constituent — not a clinical trial demonstrating that temulawak relieves dyspepsia.

Back to Table of Contents

The Regulator’s Own Arithmetic: Why the Indication Was Narrowed

This is worth walking through because the EU assessor did the arithmetic explicitly, and it is a model of exactly the kind of reasoning this doctrine asks for. Separately from the Rasyid human studies, animal pharmacology (Ozaki and Liang, 1988, cited in the EU assessment report) found that oral essential oil or isolated curcumin increases bile secretion in rats — but only at 300 mg/kg body weight. Scaled to a 60 kg adult and expressed as curcumin content, the assessor calculated that the dose required to demonstrate a measurable effect on bile secretion in the animal model is roughly 70 times higher than the maximum daily curcumin content (70 mg) actually delivered by the monograph’s own approved doses.

The assessor’s conclusion, quoted directly: “it is not likely that a significant effect of curcumin on bile secretion is obtained at doses traditionally used.” This is why the final approved indication reads “feelings of fullness, slow digestion and flatulence” rather than anything mentioning bile secretion directly — an earlier draft indication referencing “digestive complaints related to insufficient bile secretion” was explicitly narrowed for two independent reasons: the dose gap just described, and a separate, more interesting objection that a lack of bile secretion “cannot be diagnosed without the help of a medicinal practitioner,” and Article 16a of the governing directive requires a traditional-use indication to describe something the patient can recognise and self-treat, not a physiological mechanism only a clinician could confirm.

That second objection is worth sitting with. It means the final wording of the approved indication is not simply softened marketing language — it is what remains after a regulator asked, explicitly, “can an ordinary person actually diagnose the thing this product claims to treat?” and answered no for the mechanism-based version but yes for the symptom-based one.

The Underlying Mechanism, In the Regulator's Own Words

The EU assessment report’s non-clinical review adds mechanistic texture the main page does not have room for. Ozaki and Liang (1988) found that Curcuma xanthorrhiza essential oil produced a slightly stronger cholagogic (bile-increasing) effect in rats than Curcuma longa essential oil at the same dose, and traced the active principle within the essential oil to d-camphor — not xanthorrhizol or curcumin. Separately, Siegers and colleagues (1997) found that intravenous curcumin and bisdesmethoxycurcumin increased bile flow in rats by 80% and 120% respectively within two hours, establishing curcuminoids as a second, independent bile-stimulating mechanism. Yasni and colleagues (1991) found that rats fed 5% powdered Curcuma xanthorrhiza root showed a 30% reduction in faecal bile acid excretion, consistent with reduced total bile acid pool size — a related but distinct finding about bile acid handling generally, not acute secretion.

Three separate mechanistic threads (essential oil/camphor, curcuminoids, and bile acid pool size), converging on the same general direction — increased bile flow and altered bile acid handling — is a more coherent mechanistic picture than most traditional digestive herbs can offer. It is still, outside of the two Rasyid human trials above, entirely animal pharmacology.

Back to Table of Contents

Appetite in Children: The Household Use

The main page correctly identifies appetite stimulation in children as the most common everyday Indonesian use of temulawak, and correctly notes the trials behind it are small and not the kind that would support a medical claim. One addition worth making here: this specific use — children’s appetite — sits entirely outside the EU monograph, which explicitly excludes children and adolescents under 18 for lack of adequate safety data. A European regulator examining the same plant that Indonesian parents give their children daily concluded there was not enough data to recommend it for that age group at all. This is not necessarily a safety alarm — food-level exposure via a sweetened traditional drink is a different question from a standardised extract dosed for a paediatric indication — but it is a real gap between the two traditions’ risk tolerance worth naming plainly.

A Related but Distinct Finding: Gastroprotection From the Leaf, Not the Rhizome

One further study is worth including precisely because it needs a caveat the marketing copy would skip. Rahim and colleagues (2014, Universiti Malaya) tested an ethanolic extract of Curcuma xanthorrhiza leaf against ethanol-induced gastric ulcers in rats, at 250 and 500 mg/kg against an omeprazole (a standard antacid drug) positive control. The result was a genuine, measurable gastroprotective effect: reduced ulcer area, less histological mucosal damage, elevated protective prostaglandin E2 and superoxide dismutase, and reduced oxidative-damage markers, with no sign of toxicity up to 5 g/kg in acute testing.

The reason this needs its own paragraph rather than a place in the choleretic-mechanism discussion above: it tested the leaf, not the rhizome. Every other claim on this page and on the main article — traditional use, the EU monograph, the Commission E indication, both Rasyid trials — concerns the rhizome, the part that is actually traded, dried, and made into the traditional drink or the European extract products. A leaf-extract result is a genuine, separate finding about a different plant part, not confirmation of the rhizome's gastroprotective potential, following the same part-substitution caution this site applies elsewhere (a root result should not be read onto a leaf preparation, and the reverse is equally true here). It is included because it is real, on-species, and mechanistically interesting — a second, PGE2/antioxidant-mediated protective mechanism distinct from the bile-flow story above — not because it extends the traditional rhizome claim.

Verdict and Evidence Tier

• Tier: a genuine traditional-use regulatory registration, resting on real human pharmacology (gallbladder contraction) rather than clinical outcome trials, with the regulator's own reasoning fully public and precise. This is a different and, in some ways, better-documented evidence tier than “absent,” “negative,” or “old, weak and positive” — it is a case where the exact boundary of what is and is not known has been formally drawn by a regulatory body, in public, with its reasoning shown.
• Verdict on the choleretic mechanism: real and multiply demonstrated in animals, with human confirmation of the downstream physiological effect (gallbladder contraction) but not of any clinical outcome, and at a dose the regulator itself calculated is unlikely to be reached by traditional intake.
• Verdict on symptomatic relief of dyspepsia specifically: never directly tested in humans. No trial has given a person with diagnosed dyspepsia, bloating or slow digestion actual temulawak and measured whether their symptoms improved. The approved indication rests on plausibility and tradition, exactly as Article 16a requires, not on a symptom-relief trial.
• Verdict on the two Rasyid trials specifically: real, human, dose-responsive, and precisely characterised — the strongest data point in this entire four-part series — but testing isolated curcumin, a compound shared with ordinary turmeric, against a surrogate marker, not the whole herb against a clinical endpoint.

Back to Table of Contents

What Is Not Known

1. No trial has tested temulawak, in any preparation, against a validated dyspepsia symptom score, quality-of-life measure, or any other clinical outcome.
2. No trial has tested the whole herb or a xanthorrhizol-standardised extract against gallbladder function — both Rasyid trials used isolated curcumin.
3. No pharmacokinetic data exist for xanthorrhizol in humans at all — the compound that chemically distinguishes this species from ordinary turmeric has never been the subject of a human dosing study.
4. No data establish a dose-response relationship between the traditional tea (1 g infused) and any measurable digestive endpoint; the dose-response data that exist (the second Rasyid trial) used purified curcumin capsules, not the rhizome preparation people actually drink.
5. No data on long-term (months to years) daily use of concentrated extracts exist, despite that being how the traditional drink is actually consumed by many Indonesians.
6. No reproductive toxicity, genotoxicity or carcinogenicity testing has been performed on the herbal substance itself — only on isolated curcumin — which the EU assessment report states explicitly is the reason the substance could not be recommended for the EU’s simplified safety “list” procedure despite its long history of use.

Practical Cautions

The EU monograph's own restrictions are the most authoritative practical guidance available for this specific use: adults only (not children or adolescents under 18); stop and see a doctor if symptoms persist beyond two weeks or worsen; avoid in pregnancy and breastfeeding (safety not established); and avoid — per the warning discussed in full on the liver deep-dive — in bile duct obstruction, cholangitis, liver disease, gallstones or any other biliary disease. Mild gastrointestinal side effects (dry mouth, flatulence, gastric irritation) are expected at an unknown frequency, and no serious adverse event or overdose has been reported to any of the three pharmacovigilance databases (German BfArM, Dutch LAREB, Thai Health Products Vigilance Center) the EU assessment report surveyed.

Back to Table of Contents

Key Research Papers

1. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Alimentary Pharmacology & Therapeutics. 1999;13(2). The original double-blind, placebo-controlled trial.
2. Rasyid A, Rahman AR, Jaalam K, Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pacific Journal of Clinical Nutrition. 2002;11(4). The dose-ranging follow-up (20/40/80 mg).
3. Hentschel C, Eglau MC, Hahn EG. [Curcuma xanthorrhiza (Java turmeric) in clinical use]. Fortschritte der Medizin. 1996;114(27). German-language clinical-use review confirming the choleretic effect in both experimental and clinical studies.
4. Rahim NA, Hassandarvish P, Golbabapour S, Ismail S, Tayyab S, Abdulla MA. Gastroprotective effect of ethanolic extract of Curcuma xanthorrhiza leaf against ethanol-induced gastric mucosal lesions in Sprague-Dawley rats. BioMed Research International. 2014. The leaf-specific gastroprotection finding discussed above — note the plant part.
5. Rahmat E, Kang Y. Javanese turmeric (Curcuma xanthorrhiza Roxb.): ethnobotany, phytochemistry, biotechnology, and pharmacological activities. Evidence-Based Complementary and Alternative Medicine. 2021. A comprehensive modern review covering the traditional-use record.
6. Siegers C-P, et al. [Choleretic effects of curcumin and demethoxycurcumin in rats]. Cited in the EU assessment report for the intravenous bile-flow finding. 1997 — live search.
7. Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Curcuma xanthorrhiza Roxb. rhizoma. European Medicines Agency, EMA/HMPC/604600/2012. Adopted 28 January 2014. The primary regulatory document quoted throughout this page.
8. Committee on Herbal Medicinal Products (HMPC). Assessment report on Curcuma xanthorrhiza Roxb. rhizoma. European Medicines Agency, EMA/HMPC/604598/2012. Adopted 28 January 2014. The full evidentiary review, including the arithmetic and named studies discussed above.
9. Blumenthal M, et al. (eds). The Complete German Commission E Monographs. American Botanical Council, 1998. Javanese turmeric monograph, “dyspeptic complaints… choleretic action.” 1990 monograph — live search.
10. Wahono CS, et al. Effect of Curcuma xanthorrhiza supplementation on systemic lupus erythematosus patients with hypovitamin D. International Journal of Rheumatology. 2017. The one registered, double-blind human RCT of the whole species — discussed in full on the chemistry deep-dive, referenced here because it used an oral 60 mg/day dose relevant to this page’s dosing discussion.
11. Curcuma xanthorrhiza and choleretic/cholagogue activity — live search.
12. Curcuma xanthorrhiza and dyspepsia — live search.
13. EMA herbal medicine overview page — Curcumae xanthorrhizae rhizoma (external, not PubMed — the regulator's own public summary).

Connections

• All Herbs
• Javanese Turmeric / Temulawak (Curcuma zanthorrhiza) — the main article.
• Javanese Turmeric Benefits Deep Dive — the hub.
• Hepatoprotective and Liver Claims — the same choleretic mechanism discussed here, read as a caution rather than a benefit.
• Xanthorrhizol: Anti-Inflammatory and Anticancer Research.
• Antimicrobial and Oral-Health Research.
• Turmeric (Curcuma longa) — the shared curcumin literature referenced throughout.
• Dandelion — another European choleretic tradition with a comparable regulatory footing.
• Artichoke Leaf — the better-known European bitter/choleretic digestive herb.
• Gastroenterology.
• Gallstones.

Back to Table of Contents